This ex­trav­a­gant par­ty dur­ing #BIO18 fea­tured top­less dancers, and in­dus­try lead­ers are not pleased

An in­fa­mous in­dus­try par­ty held dur­ing the BIO In­ter­na­tion­al Con­ven­tion in Boston last week has come un­der fire for fea­tur­ing scant­i­ly clad fe­male dancers with spon­sor lo­gos paint­ed on their bod­ies.

Kate Stray­er-Ben­ton

Af­ter an at­tendee, Kate Stray­er-Ben­ton, pro­vid­ed pho­tos of the Par­ty at Bio Not As­so­ci­at­ed with Bio (bet­ter known as PAB­NAB) to the me­dia and open­ly spoke against it, some spon­sors as well as of­fi­cials of the trade group re­act­ed with a mix of con­dem­na­tion and dis­ap­point­ment.

Stray­er-Ben­ton — di­rec­tor of strat­e­gy at Mo­men­ta Phar­ma — told Bio­Cen­tu­ry, which first re­port­ed the news, that the en­ter­tain­ment was “be­yond tone-deaf.”

“We can talk all we want about di­ver­si­ty on pan­els and in the board­room, but when events like this are com­mon­place, I just think it un­der­mines all the progress be­ing made by in­dus­try groups and drug com­pa­nies,” Stray­er-Ben­ton elab­o­rat­ed to STAT. “I just think we take gi­ant steps back­wards when some­thing like this is con­sid­ered ac­cept­able.”

Mar­ti­na Mols­ber­gen

Now in its 14th year, PAB­NAB is known for its ex­trav­a­gant vibe in di­rect con­trast to the net­work­ing event that it’s in a sense born out of — but em­phat­i­cal­ly not af­fil­i­at­ed with.

C14 Con­sult­ing Group, one of three or­ga­niz­ers of this year’s event, al­so helped or­ga­nize last year’s event and was a spon­sor in 2016, ac­cord­ing to so­cial me­dia records. CEO Mar­ti­na Mols­ber­gen told Bio­Cen­tu­ry that last week’s par­ty was “edgy and art­sy” — and in line with what its spon­sors have come to ex­pect.

She added that C14 has re­ceived “very pos­i­tive feed­back from spon­sors” who “were very hap­py with the par­ty and the way it went, and did not feel un­com­fort­able,” but Bio­Cen­tu­ry not­ed she de­clined to name any spe­cif­ic spon­sors who had been in touch.

An­na Chris­man, man­ag­ing di­rec­tor of EBD Group, said she was con­cerned about the dancers’ pres­ence at the par­ty but want­ed to make sure the or­ga­niz­ers were not mis­rep­re­sent­ed (EBD was one of five gold spon­sors of the event):

EBD has sup­port­ed Pab­nab for a num­ber of years. We don’t see it as a cor­po­rate re­cep­tion, but a place that cel­e­brates friend­ships in the biotech com­mu­ni­ty. Un­for­tu­nate­ly, this year we were un­aware of the dancers un­til we ar­rived on site. We do not con­done this el­e­ment of the par­ty, and we voiced our con­cern on­site and af­ter­wards and know that this will not hap­pen again. The or­ga­niz­ers are main­ly women, and among them are suc­cess­ful, out­spo­ken fe­male ex­ec­u­tives who have been trail­blaz­ers for women in this in­dus­try. There are many things that can be said about this par­ty, but it is not run by or for the “old boys club.”

An­na Chris­man

In ral­ly­ing against PAB­NAB’s em­ploy­ment of fe­male dancers, Stray­er-Ben­ton bor­rowed from Bio­Cen­tu­ry pres­i­dent Karen Bern­stein and SV Life Sci­ences Ad­vis­ers man­ag­ing part­ner Kate Bing­ham, who wrote an open let­ter to the bio­phar­ma in­dus­try in 2016 af­ter at­tend­ing “yet an­oth­er cock­tail par­ty in which in­ap­pro­pri­ate­ly clad women served as eye can­dy” at the JP Mor­gan con­fer­ence.

The event ref­er­enced was a LifeSci Ad­vi­sors af­ter par­ty, which hired a num­ber of young fe­male mod­els to es­cort guests. The let­ter sparked con­sid­er­able out­rage, with some 230 sig­na­tures from in­dus­try lead­ers. LifeSci Ad­vi­sors even­tu­al­ly apol­o­gized, and has since launched ini­tia­tives to ad­dress gen­der di­ver­si­ty in com­pa­nies.

John Maraganore

Stray­er-Ben­ton took a sub­stan­tial por­tion of Bern­stein and Bing­ham’s let­ter but rewrote some of it to re­flect the PAB­NAB event. It reads, in part: “We ac­knowl­edged in 2016 that it was time for us, as se­nior women and men in the in­dus­try, to say ‘Enough.’ So, how is it, in this world where #Time­sUp and #Me Too have shown the spot­light on so many in­dus­tries, an ‘af­ter par­ty’ spon­sored by com­pa­nies with­in our own in­dus­try fea­tures top­less [fe­male] dancers?”

Sara De­my, whose firm De­my-Colton al­so spon­sored the event, said she was not in­volved in the or­ga­ni­za­tion of the event and is “sad­dened and dis­ap­point­ed by what tran­spired.”

“It is was ab­solute­ly not okay. Not to­day, not ever,” she wrote in an email. “There was a troupe of 40+ Broad­way wor­thy dancers, who went through mul­ti­ple cos­tume changes while I was there. It wasn’t un­til I was on my way out that I no­ticed the oth­er dancers. Frankly, it made me ill.”

BIO ex­ec­u­tives took note. STAT re­port­ed that the com­mit­tee on work­force de­vel­op­ment, di­ver­si­ty, and in­clu­sion dis­cussed the event on an emer­gency phone call on Tues­day and de­cid­ed mem­bers who con­tin­ue to spon­sor the even would not be wel­come in the trade group. Ken Li­saius, BIO’s SVP of com­mu­ni­ca­tions, lat­er clar­i­fied that since the event con­flict­ed with their prin­ci­ples, they would en­cour­age mem­bers to speak to event or­ga­niz­ers to en­sure fu­ture events fea­ture “more ap­pro­pri­ate en­ter­tain­ment.”

“We can­not stand for an event like that that is de­bas­ing and is frankly not con­sis­tent with our stan­dards around in­clu­sion,” said John Maraganore, BIO chair­man and CEO of Al­ny­lam, to STAT.

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.

With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.

Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.